Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Short term Debt (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Short term Debt for 4 consecutive years, with $37944.0 as the latest value for Q2 2025.

  • Quarterly Short term Debt fell 75.07% to $37944.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $37944.0 through Jun 2025, down 75.07% year-over-year, with the annual reading at $110517.0 for FY2024, 26.37% down from the prior year.
  • Short term Debt for Q2 2025 was $37944.0 at Inhibikase Therapeutics, down from $74772.0 in the prior quarter.
  • The five-year high for Short term Debt was $152224.0 in Q2 2024, with the low at $37944.0 in Q2 2025.
  • Average Short term Debt over 4 years is $129475.2, with a median of $146368.5 recorded in 2022.
  • The sharpest move saw Short term Debt grew 4.92% in 2023, then crashed 75.07% in 2025.
  • Over 4 years, Short term Debt stood at $145836.0 in 2022, then increased by 2.92% to $150095.0 in 2023, then decreased by 26.37% to $110517.0 in 2024, then crashed by 65.67% to $37944.0 in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $37944.0, $74772.0, and $110517.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.